Eckert & Ziegler: Large-Scale Contracts for MultiSource Radiation Systems

(PresseBox) ( Berlin, )
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700), a specialist in cancer diagnostic and treatment products, has increased its role as a provider of radiation therapy products in the Commonwealth of Independent States (CIS) via the acquisition of several large-scale contracts. Commissioned by the Kazakh, Ukrainian, and Russian governments as well as by the International Atomic Energy Agency, headquartered in Vienna, Eckert & Ziegler's Berlin-based subsidiary BEBIG GmbH will be supplying a dozen cancer clinics in Kazakhstan, the Ukraine, Russia, and Armenia with the "MultiSource" tumor radiation systems before the end of this year. The contracts have a total volume of well over 2 million EUR.

Dr. Edgar Löffler, Eckert & Ziegler AG's Executive Board member in charge of the therapy segment explains that "the installation of these systems offers significant support for the fight against cancer in these regions. The installations will additionally strengthen our market position in the CIS, where the introduction of our innovative, cost-saving radiation sources has been very well received, not only by specialists in the field, but also by the international organizations that subsidize such systems. We therefore anticipate that our "MultiSource" high dose radiation system (HDR) will continue to be highly esteemed by its buyers and users."

HDR brachytherapy is a minimally invasive patient friendly, ambulant radiation procedure whereby a miniature radiation source is placed inside the body in very close proximity of the tumor. This reduces unnecessary patient radiation exposure and leads to better treatment results.

About Eckert & Ziegler BEBIG GmbH Eckert & Ziegler BEBIG GmbH has been manufacturing radiation therapy products for more than sixteen years, and has in many countries acquired a leading market position for tumor radiation systems. The company is also Europe's leading producer of implants for the treatment of prostate cancer.

Eckert & Ziegler AG is an internationally active specialist for radioactive applications in medicine, science, and industry. Listed on the Frankfurt Prime Standard, the company posted sales of 54 million EUR in 2007, and currently has approximately 430 employees.
The publisher indicated in each case is solely responsible for the press releases above, the event or job offer displayed, and the image and sound material used (see company info when clicking on image/message title or company info right column). As a rule, the publisher is also the author of the press releases and the attached image, sound and information material.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to